Dr. Levin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10970 Shadow Creek Pkwy
Ste 280
Pearland, TX 77584Phone+1 713-436-7500Fax+1 713-436-7505
Summary
- Dr. Pavel Levin, located in Pearland, TX, is an experienced Oncologist who specializes in thoracic oncology. His education includes a Fellowship in Hematology and Medical Oncology, as well as a Residency in Internal Medicine from the University of Texas Southwestern Medical Center. Additionally, he holds a Ph.D. in Cancer Biology from MD Anderson Cancer Center and a BS in Biology from the University of Houston. Since 2017, he has been practicing as a Physician at Texas Oncology. Dr. Levin's research has been widely cited in prominent publications in his field, and he has also been part of clinical trials such as the Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2017- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2011 - 2013
McGovern Medical School at UTHealthClass of 2011
MD Anderson Cancer CenterPh.D., Cancer Biology, 2005 - 2010- University of HoustonBS, Biology, Summa Cum Laude, Highest GPA in the College of Natural Sciences and Mathematics (Banner Bearer), 1999 - 2002
Certifications & Licensure
TX State Medical License 2013 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer. Start of enrollment: 2016 Nov 01
Publications & Presentations
PubMed
- 99 citationsNuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer CellsXue Pan, Thiruvengadam Arumugam, Tameyoshi Yamamoto, Pavel A. Levin, Vijaya Ramachandran
Clinical Cancer Research. 2008-12-15 - 35 citationsAxl Receptor Axis: A New Therapeutic Target in Lung CancerPavel A. Levin, Rolf A. Brekken, Lauren Averett Byers, John V. Heymach, David E. Gerber
Journal of Thoracic Oncology. 2016-08-01 - 16 citationsSpotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to datePavel A. Levin, Jonathan E. Dowell
Oncotargets and Therapy. 2017-04-07
Press Mentions
Texas Researchers Summarize Promising Research on New Mesothelioma Drug, According to Surviving MesotheliomaMay 2nd, 2017
Professional Memberships
- Member
- Member
- Member
Other Languages
- Russian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
